The Cancer Hospital of Chinese Academy of Medical Sciences (hereinafter referred to as the Cancer Hospital of the Academy of Medical Sciences) is the first specialized cancer hospital in China. This hospital also represents the cutting-edge power of tumor diagnosis, treatment and research in China. The hospital has been ranked first for 12 consecutive years in the Fudan version of the national comprehensive ranking of oncology specialties. Under the background of national promotion of graded diagnosis and treatment and accelerating the construction of medical association, the Cancer Hospital of the Academy of Medical Sciences, as the national leader in cancer diagnosis and treatment, has assumed the important task of implementing the leading role of disciplines and supporting the lower-level primary hospitals.

Recently, DHC's new digital oncology radiotherapy solution was officially launched in the Cancer Hospital of the Academy of Medical Sciences. The solution uses big data, AI and other digital technologies to cover the whole process of "diagnosis + treatment", and is dedicated to promoting the expansion of high-quality medical resources in radiotherapy. Meanwhile, it provides national tumor hospitals with high quality resources, promotes the standardization and homogenization of tumor treatment, and creates a model of radiotherapy medical association.

DHC Digital Oncology Radiotherapy Solution, Providing Hospitals with One-Stop Full Coverage Service

Radiotherapy is one of the important methods to treat tumors. With the national planning and promotion, more and more hospitals have introduced advanced radiotherapy equipment. However, given the many radiotherapy sessions, complex processes and strong professionalism, the supply and demand gap of domestic radiotherapy talents is still huge, especially the training of radiotherapy professionals is difficult to achieve a breakthrough in the short term. The cooperation between DHC and the radiotherapy department of the Cancer Hospital of the Academy of Medical Sciences will ease the bottleneck of talents in China and set off a new wave of innovative service models in the field of radiotherapy.

Through the "cloud + radiotherapy" model, DHC relies on its products and services, including tele-radiotherapy consultation system, radiotherapy quality control platform, radiotherapy standard database, and multi-center clinical trial management platform. The company is the first to successfully implement the construction of radiotherapy medical association in the Cancer Hospital of the Chinese Academy of Medical Sciences, providing cloud-based, software and hardware-integrated digital radiotherapy solutions from clinical to scientific research.

The solution not only relies on DHC's own R&D and innovation of many leading products, but also supports DHC's strategic partner, medical technology giant Philips' technology and innovation advantages accumulated in the radiotherapy field for many years. It can realize the whole process of radiotherapy, from image diagnosis, simulation positioning, treatment planning, treatment implementation, quality control and follow-up evaluation.

DHC's digital oncology radiotherapy solution is compatible and interoperable with both hardware and software equipment in hospital radiotherapy departments. It is compatible with different manufacturers and different types of radiotherapy equipment, and can also adapt to different radiotherapy workflows, making it easy for hospitals to deploy and use it quickly.

Promote the construction of the Putative Consortium to expand the capacity for high-quality medical resources

In recent years, the policies of promoting graded treatment and exploring the establishment of medical consortia and other modes of division of labor and collaboration have emerged frequently. The service model of radiotherapy medical consortium under the concept of "Internet+Radiotherapy" mainly employs advanced Internet technology to realize the cloud-based design of radiotherapy. It has become an effective way to improve the capability of primary cancer treatment.

Through DHC's tele-radiotherapy consultation system, CAS Cancer Hospital can provide guidance to doctors and physicists in primary hospitals, and sink the hospital's internal high-quality resources, technologies and treatment concepts to the primary level. Meanwhile, with the help of DHC's radiotherapy quality control platform, CAS Cancer Hospital provides equipment quality control homogeneous management to the primary hospitals, enabling CAS Cancer Hospital to realize a flexible, efficient and comprehensive working mode of counseling the grassroots and facilitating the inter-hospital quality control level to a higher platform.

The teleconsultation function linked between the higher-level hospital and the primary hospital transforms the traditional mode of on-site assistance by medical technicians to the primary hospital into a teleconsultation service conducted online. This new form has significantly improved the communication efficiency of inter-hospital diagnosis and treatment and effectively reduced various costs.

Li Yexiong Director, Department of Radiotherapy, Cancer Hospital, Chinese Academy of Medical Sciences

As the relying unit of the National Cancer Center, the successful operation of the medical association model of the Cancer Hospital of the Academy of Medical Sciences has significant benchmarking significance. The hospital will be able to better play the downward radiation support role of the national cancer hospital and effectively alleviate the problems of insufficient talent reserve and inconsistent medical standards in radiotherapy at the grassroots level. Professor Li Yexiong, director of radiotherapy department of Cancer Hospital, Academy of Medical Sciences, indicates that the model of radiotherapy consortium can be promoted in a wider scope. This can help the development and expansion of the grassroots hospitals and even bring systematic improvement to the radiotherapy industry nationwide.

Dual assistance of radiotherapy-specific database and scientific research platform to empower smart radiotherapy 

In addition, DHC gives full play to its advantages in the field of big data and artificial intelligence, and joins hands with the Cancer Hospital of the Academy of Medical Sciences. Its aim is to build a road of confidence in the treatment of tumor patients with the hospital through deep governance of radiotherapy data.

It is well known that data is the foundation of clinical research. However, the value of clinical data is often greatly reduced because it is difficult to collect and process, and cannot be interconnected. At present, DHC has established a complete technical system related to the life cycle of big data. The radiotherapy standard database and multi-center clinical trial management platform built by the Cancer Hospital of the Academy of Medical Sciences this time is conducive to releasing the working time of medical staff and playing an important role in improving the clinical, scientific research and teaching of radiotherapy discipline in all aspects.

DHC has been committed to providing support for the improvement of tumor diagnosis and treatment. As an important member of the national tumor database, DHC has undertaken the project of national tumor data center and tumor data platform. Moreover, the company attaches great importance to data security and privacy management. The radiotherapy cloud system has been certified by the Ministry of Public Security as Level 3 Equal Security.

The digital radiotherapy solution is clinically able to provide specific guidance during hospital treatment, while the establishment of the online research management platform promotes more standardized and efficient clinical research. The completion of the solution was highly recognized by Prof. Yexiong Li.

Prof. Yexiong Li said that in the future, he and DHC will continue to deepen cooperation in expanding the audience, expanding clinical indications, and improving clinical research, so that more patients can enjoy advanced radiotherapy technology and standardized treatment services more conveniently.

He believes that after the successful implementation of this innovative digital oncology radiotherapy solution in more provincial oncology and primary hospitals, it will promote a new stage of rapid development of radiotherapy in China, contributing to the graded treatment of cancer in China and benefiting mass cancer patients.